Insight
Beyond Clinic
Insight

Information about skin treatments, common questions, and care decisions.

Skin & Regeneration

Experimental Studies Link NAD+ to Skin Repair, but Human Skin Research Is Still Preliminary

Written by Beyond Clinic editorial team · Medically reviewed by Hyojung Moon, MD · Published

Skin cells use NAD+ (nicotinamide adenine dinucleotide) in energy metabolism and in repairing DNA (deoxyribonucleic acid, which carries genetic information). Experimental studies have linked NAD+ to skin repair. Studies applying NAD+ to human skin, however, remain small and preliminary. Whether cells need a substance, whether it reaches them, and whether skin outcomes change are separate questions.

ASLS 2026 talk series: ① Evidence and limits (this article) · ② Talk findings and limits of uncontrolled observations · ③ At the ASLS 2026 talk.

About this article

This article explains research and safety information assembled for a presentation at ASLS KOREA 2026 AUTUMN CONGRESS on November 8, 2026. It does not recommend starting or stopping an ingredient or medicine; discuss prescribing and discontinuation with a clinician. The site editorial team did not author the cited studies. The series speaker, Hyojung Moon, MD, is also this article’s medical reviewer and disclosed Vitamedical (C) on slide 2. The meaning of C has not been confirmed. This article does not assess authorization, classification, or indications in Korea.

Review scope

The literature set contains 254 publications collected through the November 6, 2026 search cutoff: 246 indexed in PubMed, a biomedical literature database, and 8 not indexed there. It includes biological reviews; cell, animal, and excised-tissue experiments; human studies; assessment methods; and reporting guidance. This is a publication count, not a count of independent clinical trials or participants. Three retracted original studies were excluded from efficacy interpretation.

Key points

  • Experimental studies support a connection between NAD+ and skin repair. Human studies of topical application, including application after microneedling, remain small and preliminary.
  • Niacinamide studies of pores, acne, and pigmentation provide background. Niacinamide is a different molecule, so those findings do not establish effects of NAD+ skin injections.
  • Crossing the skin barrier, reaching viable skin layers, crossing a cell membrane, raising intracellular NAD+, and producing a clinical benefit each require verification.
  • Early human skin findings include melasma and psoriasis. Within this literature set, no published controlled trial was identified that tested the added benefit of NAD+ skin injections for pores or acne.
  • Safety depends on formulation, route, accompanying procedures, and observation time. Data on long-term effects of repeated local exposure and drug interactions remain limited.

First, the basics: what NAD+ does in skin

NAD+ is naturally present in cells. As a coenzyme, it helps enzymes carry out chemical reactions, including those that obtain energy from nutrients. NAD+ accepts electrons to become NADH and can return to NAD+ during energy metabolism. Supplying NAD+ is not the same as supplying energy itself. Some studies measure NAD+ alone and others include NADH, so a measurement may be called NAD.[1]

Some enzymes that respond to DNA damage use NAD+, as do sirtuins, enzymes involved in cellular stress adaptation. These reactions break down NAD+, which cells must then synthesize again. Recycling between forms and consumption by enzymes are distinct processes.[1]

NAD+ metabolism is involved in how skin cells withstand damage and maintain function. These cellular roles do not determine what happens when an external formulation is applied. Cell state, the tissue reached, the molecular form delivered, and actual functional changes still need to be assessed.[1,2]

Visible pores, inflammatory acne, brown marks, red marks, and depressed scars are different concerns. Their measurements and time courses can differ even when photographs look similar. A shared NAD+ deficiency across these conditions has not been established.[2,4,5,18,19]

A closer look: findings from skin repair experiments

In studies of aged mice and mice with an epidermal gene deletion, maintaining NAD+ levels was linked to epidermal growth and repair. Treatment with NAD+ precursors also restored cell outgrowth in skin explants from aged mice. A precursor is a substance used to synthesize another molecule.[2]

These mouse experiments provide biological support for studying NAD+ metabolism in skin repair, but the administered precursors must be distinguished from NAD+ itself. Baseline mitochondrial measures showed no clear difference between gene-deleted and control mice. Mitochondria are cell structures important for energy production; the findings do not support one explanation of energy deficiency for all damaged skin.[2]

In an experiment with ultraviolet-exposed keratinocytes, the main cells of the epidermis, NAD+ depletion was also linked to cell survival, and recovery with precursors was described. Ultraviolet damage differs from microneedle or thermal injury. Reproduction of these findings in a human face is a separate question.[3]

An observational study of surgically obtained, sun-protected pelvic skin found an association between age and tissue NAD levels. Its cross-sectional design cannot establish cause and effect. The tissue was not facial skin, and the study did not describe individual cells. Age-related tissue differences cannot diagnose NAD+ deficiency in skin with visible pores or acne.[4]

Experiments that inhibit or restore synthesis help identify a pathway’s role. Whether an applied formulation produces the same change in human target cells requires separate testing. Delivery and functional benefit still need verification even when biological necessity has been shown.[1–3]

How niacinamide differs from NAD+

Niacinamide, also called nicotinamide, is a form of vitamin B3 and a precursor of NAD+. Enzymes convert it to nicotinamide mononucleotide (NMN) and then synthesize NAD+. Nicotinamide riboside (NR) is another precursor that enters NAD+ synthesis through NMN. Being part of the same pathway does not make them the same molecule.[1]

Topical niacinamide has also been studied in people. A randomized split-face trial included 25 paired facial comparisons in its 4% niacinamide-only arm. The opposite side received vehicle, a formulation without the comparison ingredient. Investigators reported a 14.7% reduction in the image-based pore count on the niacinamide side at week 8 relative to its own baseline. Comparisons between the niacinamide and vehicle sides at individual visits were not statistically significant, however, and the result did not establish persistence of that pore-count change through week 12. An image-based count is not a measurement of anatomical pore number or diameter.[5]

An inflammatory acne trial randomized 80 participants, 40 per group, to 4% nicotinamide or 1% clindamycin, an antibiotic. Investigators reported lower acne grades than baseline in both groups at 8 weeks, without a significant final between-group difference. This was not an equivalence trial: failure to detect a difference does not establish equal effects. The source also recorded minor adverse events in 14 of 40 nicotinamide recipients and 11 of 40 clindamycin recipients.[6]

A split-face pigmentation study applied 5% niacinamide to one side of the face and vehicle to the other in 18 Japanese women. Investigators reported an image-based difference in hyperpigmented area from week 4 and a visual-grading difference at week 8. In separate co-culture experiments, two cell types were grown together. These experiments found inhibition of melanosome transfer, the movement of pigment-containing organelles between cells. The cell experiment and human assessments are different results; a cellular inhibition percentage is not a percentage change in human skin color.[7]

Findings for niacinamide under these study conditions cannot establish a pore or acne effect for topical or intradermal NAD+, which differs in molecule, formulation, and delivery route. Whether NAD+ reaches cells in a form they can use needs to be checked first.[1,5–7]

Each step from skin application to cellular delivery needs testing

Experiments support the possibility that cells can use externally supplied NAD+. In one route, extracellular NAD+ breaks down and cells recover the precursors to resynthesize it. Certain cell models also report possible uptake of intact NAD+. The relative contribution of each route depends on experimental conditions; one route cannot explain absorption of every formulation applied to human skin.[8–10]

First: does it cross the outer skin barrier? The stratum corneum limits entry. Even when microneedling changes permeability, distribution depends on application timing, formulation, and procedural conditions. Delivery experiments with other substances include positive findings and failure to observe dermal deposition under particular conditions.[20,21]

Second: where does it reach within viable skin? The amount passing through skin, the amount retained, and the amount detected at a particular depth are different measurements. A needle’s depth setting does not establish the distribution depth of an applied substance. Detection in the stratum corneum cannot establish delivery to dermal cells, below the epidermis.[20,21]

Third: in what form does it cross a cell membrane? A substance in skin tissue can remain outside cells. If NAD+ is broken down and its precursors are used, intracellular resynthesis is still required. Experiments reporting intact uptake do not establish a universal route across skin cell types.[8–10]

Fourth: does intracellular NAD+ actually increase? A study using a specialized carrier on excised human skin measured tissue NAD and examined its distribution. When researchers homogenize, or grind up, tissue for measurement, it is difficult to separate extracellular administered material, native NAD, and resynthesized NAD. A laboratory finding for one carrier cannot establish residence time in the living human dermis or intracellular increases with other formulations.[11]

Fifth: does that change produce the intended skin outcome? Even if NAD levels change, pore appearance, inflammatory lesions, and skin function need their own assessments. An oral precursor trial illustrates that skin NAD measurements and primary functional outcomes need not agree.[16]

How quickly NAD+ disappears from culture medium does not tell us its half-life, the time for an amount to fall by half, in the human dermis. Breakdown, distribution, and clearance act together in living skin. For the actual applied formulation, this literature set has not established the molecular form that remains in the dermis, how long it stays, or which cell types use it.[8,11]

Human skin studies remain small and preliminary

Early studies of NAD+ applied directly to human skin have reported changes. A 2026 single-arm, uncontrolled study applied topical NAD+ after microneedling in 36 Korean women with melasma. The authors reported lower melasma scores than baseline at the reported week-21 assessment. Without a comparator, the contributions of microneedling, photoprotection, natural course, and NAD+ cannot be separated. Timing descriptions also differ, so this cannot confidently be called 21 weeks after the final treatment.[12]

A 2007 exploratory psoriasis study compared two similar plaques within each of 37 patients. In a separate vehicle comparison involving 11 patients, the authors reported lower plaque scores on the NAD+ ointment side at 4 weeks; randomization was not stated. Comparisons of 1% or 0.3% NAD+ ointment with 0.1% anthralin, a topical psoriasis medicine, reported similar score reductions at 4 weeks. These small comparisons do not establish equivalence. The NAD+ concentration in the vehicle comparison differs between Methods and Results. Findings for ointment on psoriasis plaques cannot be transferred to pore or acne injections.[13]

The studies below concern different conditions and measurements, so their effect sizes cannot be ranked against one another.

What was studied Human evidence and design, without a formal certainty assessment Reported finding and remaining limits
Topical NAD+ after microneedling Single-arm, uncontrolled study in 36 Korean women with melasma; very low certainty.[12] The authors reported lower melasma scores than baseline at the reported week-21 assessment. Independent NAD+ contribution and pore or acne outcomes remain unknown.
NAD+ ointment Exploratory psoriasis study in 37 patients; 11 underwent a vehicle comparison, with randomization not stated.[13] Lower plaque scores than vehicle were reported at 4 weeks. Concentration reporting differs, and the route differs from cosmetic injection.
Topical precursors such as NMN Small exploratory studies of combination formulations and devices; individual contributions are difficult to separate.[14] Some measures changed, but ingredient and device controls were insufficient. These are not findings from direct NAD+ application.
Oral NMN or NR Review of NMN trials and a placebo-controlled NR skin-function trial; indirect evidence for facial cosmetic outcomes.[15,16] Blood NAD-related changes differ from skin functional benefits. The NR trial did not meet its primary nerve-protection and regeneration endpoints.
Other skin booster ingredients Small randomized periocular split-face trial comparing polynucleotide, a chain of nucleotide units, with hyaluronic acid.[17] Changes in selected skin measures must be distinguished from global assessments. Another ingredient’s result cannot be assigned to NAD+.
Radiofrequency microneedling Randomized comparisons for acne or scars; indirect evidence for the added contribution of NAD+.[18,19] Changes were observed without adding NAD+. Assessing its contribution requires the same procedure and a matched vehicle.

Blood measurements and skin outcomes also need to be kept separate in oral studies. Increased blood NAD-related measures do not establish the same change in skin. A review of 12 placebo-controlled NMN randomized trials, involving 513 participants and individual trial durations of 2–24 weeks, found higher blood NAD than placebo but no significant overall effects on most glucose and lipid measures. These were not tests of skin appearance or reversal of aging.[15]

A placebo-controlled NR trial with 45 participants in the final analysis did not meet its primary endpoints of protecting small cutaneous nerve fibers from injury and promoting regeneration at 90 days. Statistical significance of the skin NAD measurement was sensitive to how outliers, unusually distant measurements, were handled. The trial did not study pores, but it shows why a metabolic measurement and functional outcome need separate confirmation.[16]

Skin booster is an umbrella marketing term for different ingredients and application methods. A controlled trial of one ingredient does not establish another ingredient’s efficacy or safety. The added benefit of NAD+ needs to be distinguished from the effects of radiofrequency (RF) microneedling itself.[17–19]

What remains unknown about safety

Early human skin studies also describe reactions after application. In the uncontrolled melasma study of 36 women receiving NAD+ after microneedling, the authors reported pain. They also reported redness (erythema) and swelling (edema) lasting 24–48 hours.[12] Post-inflammatory hyperpigmentation (PIH), a dark mark that can follow inflammation, was not reported in that study. Its small size and lack of a comparator prevent separation of the two procedures’ reactions or exclusion of rare delayed events.[12]

Participant discomfort and investigator-classified adverse events need separate reporting. A small intravenous pilot study examined how well participants tolerated an infusion over a short observation period. Those findings do not establish how well NAD+ application to skin is tolerated.[25] A separate retrospective intravenous comparison used 500 mg daily for 4 days in 6 NAD+ recipients and 8 recipients of the same dose of NR. All 6 NAD+ recipients reported moderate-to-severe discomfort during infusion, resolving after the infusion ended. The authors classified the records as having no documented adverse events; that classification does not mean participants were symptom-free and cannot supply a reaction rate for skin application.[26]

Transient pain, serious adverse events, and laboratory findings, including blood-test results, each provide different information. Short observation does not establish long-term safety with repeated application. Follow-up duration and symptom collection, such as participant diaries, need to be specified.[12,25,26]

Formulation and exposure route require their own checks. Checks need to cover every ingredient and the diluent, stability after reconstitution, information appropriate to the intended route, sterility, and endotoxin control. Endotoxins are substances from certain bacteria; they present a quality issue distinct from the ingredient’s biological action. A molecule’s natural presence in the body does not establish suitability for damaged skin or injection.

Case reports describe delayed granulomatous reactions, chronic inflammation identified by biopsy, after microneedling with topical materials. These were not NAD+ application events, and case reports cannot establish incidence. Exposure through an opened barrier differs from application to intact skin.[22]

Biology also does not support a rule that raising NAD+ always reduces inflammation. In some cell and animal models, NAD+ metabolism helped sustain inflammatory signaling. This is not evidence that the same harm occurred with NAD+ application to human skin. Long-term effects of repeated local exposure and clinical drug interactions remain insufficiently studied; shared pathways alone establish neither an absolute contraindication nor the absence of interactions.[23,24]

The FDA has received reports of burns, scarring, fat loss, disfigurement, and nerve injury with certain RF microneedling uses. These reports establish neither an incidence nor an event in this series. RF microneedling requires medical care and should not be performed at home.[27]

A separate FDA notice reports severe chills, shaking, vomiting, and fatigue after injectable compounded NAD+, sometimes requiring medical care. It warns about unsuitable food-grade ingredients and microbial or endotoxin contamination. This concerns preparation quality; it does not establish contamination or intrinsic toxicity of any formulation discussed here.[28]

Questions to clarify before a procedure

Experimental work links NAD+ metabolism to skin repair, and early studies applying it directly to human skin have reported changes. Check how each study applied the substance. Ordinary topical use, application after microneedling, and intradermal injection answer different questions.[2,3,12,13]

Check that the study examined the same area and outcome of interest. Melasma and psoriasis scores, image-based pore counts, acne lesion counts, and scar assessments are not interchangeable. Photographs need consideration of lighting, gloss, hydration, and swelling. Appearance cannot establish collagen synthesis or an intracellular NAD+ increase.[5,12,13,18]

For a combination, ask what the comparison group received. Matching RF microneedling, vehicle, and accompanying care on sides with and without NAD+ makes an added contribution easier to estimate. A comparison of a procedure alone with the whole added formulation estimates the formulation’s contribution. If additives also differ, it cannot isolate NAD+.[18,19]

Ask about the ingredient and formulation, route, target skin concern, and human evidence under those conditions. Tell the clinician about earlier procedures, allergies, medicines, prolonged redness, or persistent lumps. Clarify which reactions may be temporary and which require reassessment.

Limits of the research and of this explanation

Research limitations differ by design. Cell and animal experiments can examine pathways closely but cannot directly determine effects or doses in a human face. Small uncontrolled studies and case reports may detect changes but cannot readily separate natural course and accompanying care. Even controlled trials address different questions if their comparator, disease, formulation, or follow-up differs.

More publications do not make every finding certain. One trial may appear in several publications, and a primary study may be counted alongside a review that cites it. Counting publications does not tell us the number of independent experiments or the strength of evidence. Small, short studies are particularly limited for rare reactions and long-term outcomes.

This explanation also has limits. It does not cover results after the search cutoff, unpublished studies, all national registries, or every publication indexed under another name. Some sources, including the ultraviolet-exposed keratinocyte study, were assessed only at abstract level. Unavailable details and results were not included in interpretation.[3]

The literature search did not identify a controlled trial within its scope; that does not establish that no research exists or that there is no effect. The positive observations should be considered alongside the unanswered questions. Further studies in human skin need a defined formulation and route to examine target cells, delivered amounts, intracellular changes, added benefit, and long-term safety.

This article explains the evidence and limits assembled for the November 8, 2026 ASLS presentation. NAD+ and related ingredient names identify research subjects and categories; they are not recommendations for a particular product or procedure. Seek medical assessment if redness persists after a skin procedure, pain or swelling worsens, or a firm lump remains.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PubMed.
  2. Wong W, Crane ED, Zhang H, Li J, Day TA, Green AE, et al. Pgc-1α controls epidermal stem cell fate and skin repair by sustaining NAD+ homeostasis during aging. Mol Metab. 2022;65:101575. PubMed.
  3. Katayoshi T, Nakajo T, Tsuji-Naito K. Restoring NAD+ by NAMPT is essential for the SIRT1/p53-mediated survival of UVA- and UVB-irradiated epidermal keratinocytes. J Photochem Photobiol B. 2021;221:112238. PubMed. Abstract-level evidence.
  4. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. PubMed.
  5. Chiu PC, Chan CC, Lin HM, Chiu HC. The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial. J Cosmet Dermatol. 2007;6(4):243-9. PubMed.
  6. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. Int J Dermatol. 2013;52(8):999-1004. PubMed.
  7. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20-31. PubMed.
  8. Kulikova V, Shabalin K, Nerinovski K, Yakimov A, Svetlova M, Solovjeva L, et al. Degradation of Extracellular NAD+ Intermediates in Cultures of Human HEK293 Cells. Metabolites. 2019;9(12):293. PubMed.
  9. Wilk A, Hayat F, Cunningham R, Li J, Garavaglia S, Zamani L, et al. Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci Rep. 2020;10(1):651. PubMed.
  10. Buonvicino D, Ranieri G, Pittelli M, Lapucci A, Bragliola S, Chiarugi A. SIRT1-dependent restoration of NAD+ homeostasis after increased extracellular NAD+ exposure. J Biol Chem. 2021;297(1):100855. PubMed.
  11. Kang S, Wei S, Koo BI, Jo Y, Park J, Xue Y, et al. Ion-coupled transfersome complexes for enhanced transdermal NAD+ repletion and mitigation of cellular senescence signatures. Mater Today Bio. 2026;38:103218. PubMed.
  12. Yi KH, Wan J, Hwang S. Efficacy and Safety of a Topical Nicotinamide Adenine Dinucleotide Skinbooster for the Treatment of Melasma. Aesthetic Plast Surg. 2026;50(11):4431-4436. PubMed.
  13. Wozniacka A, Szajerski P, Adamus J, Gebicki J, Sysa-Jedrzejowska A. In search for new antipsoriatic agents: NAD topical composition. Skin Pharmacol Physiol. 2007;20(1):37-42. PubMed.
  14. Hong W, Kim J, Noh S, Shim J, Park SK, Kim M. Beyond Nano-Delivery: … Transdermal Delivery of Nano-Formulated Nicotinamide Mononucleotide (Nano-NMN) for Comprehensive Skin Rejuvenation (abridged title). Cosmetics. 2026;13(4):172. DOI.
  15. Zhang J, Poon ET, Wong SH. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Crit Rev Food Sci Nutr. 2025;65(22):4382-4400. PubMed.
  16. Thomas S, Ben-Davies R, Cetinkaya-Fisgin A, Hu X, Li X, Stewart S, et al. Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. J Peripher Nerv Syst. 2026;31(1):e70101. PubMed.
  17. Lee YJ, Kim HT, Lee YJ, Paik SH, Moon YS, Lee WJ, et al. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial. J Dermatolog Treat. 2022;33(1):254-260. PubMed.
  18. Min S, Park SY, Yoon JY, Suh DH. Comparison of fractional microneedling radiofrequency and bipolar radiofrequency on acne and acne scar and investigation of mechanism: comparative randomized controlled clinical trial. Arch Dermatol Res. 2015;307(10):897-904. PubMed.
  19. Kwon HH, Park HY, Choi SC, Bae Y, Jung JY, Park GH. Novel device-based acne treatments: comparison of a 1450-nm diode laser and microneedling radiofrequency on mild-to-moderate acne vulgaris and seborrhoea in Korean patients through a 20-week prospective, randomized, split-face study. J Eur Acad Dermatol Venereol. 2018;32(4):639-644. PubMed.
  20. Kupwiwat R, Wanitphakdeedecha R, Wannawittayapa T, Buranaporn P, Poungpairoj P, Maneesawat T, et al. Radiofrequency Microneedling-Mediated Enhancement in Percutaneous Delivery of Topical Triamcinolone Acetonide: An In Vivo Quantitative Study. Life (Basel). 2026;16(7):1074. PubMed.
  21. Cervantes J, Chang YF, Dover JS, Hernandez Alvarez A, Chung HJ. Laser-Assisted and Device-Assisted Filler Delivery: A Histologic Evaluation. Dermatol Surg. 2023;49(9):865-870. PubMed.
  22. Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol. 2014;150(1):68-72. PubMed. An abstract correction is noted in the PubMed record.
  23. Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, et al. NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol. 2019;21(3):397-407. PubMed.
  24. Martínez-Morcillo FJ, Cantón-Sandoval J, Martínez-Navarro FJ, Cabas I, Martínez-Vicente I, Armistead J, et al. NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos cell death. PLoS Biol. 2021;19(11):e3001455. PubMed.
  25. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257. PubMed.
  26. Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PubMed.
  27. U.S. Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication. October 15, 2025. FDA.
  28. U.S. Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding. FDA.

Frequently asked questions

Does applying NAD+ increase NAD+ inside skin cells?
Experiments support this possibility, but it remains uncertain how much ordinary topical application raises NAD+ inside living human skin cells. Each step needs its own assessment: crossing the barrier, reaching a skin layer, and distinguishing extracellular residue from intracellular NAD+. Experiments using a specialized carrier on excised skin do not establish what another formulation does in a living person.[8–11] For comparison criteria, see Skin Booster Ingredients and Materials. Ask the clinician for measurements relevant to the actual formulation and route.

How do niacinamide and NAD+ differ?
Niacinamide is a precursor used to make NAD+, while NAD+ is the coenzyme used in cellular reactions after synthesis. Check the molecule, concentration, route, and comparator. Niacinamide studies have reported changes in image-based pore counts, acne grades, and pigmentation, with different comparison and follow-up limits; these are not NAD+ findings.[1,5–7] See Niacinamide: Reading Ingredient Names and Product Labels Separately. During a consultation, clarify which ingredient the cited study actually tested.

Do oral NMN or NR supplements benefit the skin?
Increases in blood NAD-related measures have been reported, but skin benefits require separate testing. Interpretation depends on the population, substance, tissue measured, and functional outcome. An NR placebo-controlled trial did not meet its primary small-nerve-fiber protection and regeneration endpoints, and it did not directly test facial cosmetic outcomes.[15,16] Regeneration, Ingredients, and Skin Boosters provides an overview of ingredient topics. Tell the clinician about supplements and medicines you take.

Have studies applied NAD+ directly to human skin?
Yes, but these are small, preliminary studies. A single-arm, uncontrolled melasma study applied NAD+ after microneedling in 36 Korean women. An exploratory psoriasis study involved 37 patients and compared two similar plaques within each patient. A vehicle comparison involved 11 of them; randomization was not stated. The disease, sample, comparator, and route limit interpretation; neither study establishes a pore or acne injection effect.[12,13] Polynucleotide Injections: A Systematic Review Reporting Changes in Wrinkles and Skin Texture offers another example of reading ingredient evidence. Ask which findings address your own skin concern.

How much is known about safety?
Early studies report reactions after application, but long-term safety with repeated skin exposure remains insufficiently characterized. Participant discomfort, investigator-classified adverse events, serious events, laboratory findings, and follow-up are different kinds of information. Small, short studies cannot exclude rare delayed reactions, and oral or intravenous findings cannot be transferred directly to skin application.[12,22,25,26] See Suspected Adverse Events After a Procedure: What to Know. Disclose allergies and any prolonged reaction after an earlier procedure.

Can the same evidence explain NAD+ used in a procedure?
Evidence cannot be transferred directly when the formulation, delivery route, or application site differs. Check all ingredients, actual exposure, accompanying procedures, and comparator. Ointment studies and application after microneedling differ from intradermal injection; delivery experiments with other substances do not establish intracellular NAD+ delivery.[12,13,20,21] See Water-Glow Injection: A Name to Distinguish from Skin Boosters. Ask whether the proposed application matches the method studied.

What should I clarify during a consultation?
Clarify the skin problem, formulation and route, and how change would be assessed. When reading human studies, check the disease studied, comparator, follow-up, and method of collecting reactions. Combination observations cannot readily separate each component's contribution, and photographs do not measure intracellular change.[11–13,18,19] See A Map of Skin Surface Concerns: First Questions About Pores, Texture, Acne Marks, and Pigment Changes. Describe symptoms, earlier procedures, and medicines, and ask which reactions are expected and which need reassessment.

Related reading

Read the Korean original

Questions about your care

Discuss questions about your care with our clinical team.

Once you verify your identity using a passport issued outside Korea, you can book without a Korean phone number. If you have trouble booking, message us on WhatsApp.

Beyond Clinic

Address
6th Floor, JY Building, 826 Nonhyeon-ro, Gangnam-gu, Seoul, South Korea
Contact
+82-2-6408-2080 · +82-2-6408-2081
Business Hours
Mondays and Fridays · 10:00 a.m.–8:00 p.m. · Last appointment at 7:00 p.m.Tuesdays and Thursdays · 10:00 a.m.–7:00 p.m. · Last appointment at 6:00 p.m.Saturdays · 10:00 a.m.–4:00 p.m. · Last appointment at 3:00 p.m.Lunch break: 2:00–3:00 p.m. (no lunch break on Saturdays)Closed Wednesdays, Sundays, and public holidays.